We studied the presence of benign infantile epilepsy (BIE), paroxysmal kinesigenic dyskinesia (PKD), and PKD with infantile convulsions (PKD/IC) in patients with a 16p11.2 deletion including PRRT2 or with a PRRT2 lossof-function sequence variant. Index patients were recruited from seven Dutch university hospitals. The presence of BIE, PKD and PKD/IC was retrospectively evaluated using questionnaires and medical records. We included 33 patients with a 16p11.2 deletion: three (9%) had BIE, none had PKD or PKD/IC. Twelve patients had a PRRT2 sequence variant: BIE was present in four (p = 0.069), PKD in six (p < 0.001) and PKD/IC in two (p = 0.067). Most patients with a deletion had undergone genetic testing because of developmental problems (87%), whereas all patients with a sequence variant were tested because of a movement disorder (55%) or epilepsy (45%). BIE, PKD and PKD/IC clearly showed incomplete penetrance in patients with 16p11.2 deletions, but were found in all and 95% of patients with a PRRT2 sequence variant in our study and a large literature cohort, respectively. Deletions and sequence variants have the same underlying loss-of-function disease mechanism. Thus, differences in ascertainment have led to overestimating the frequency of BIE, PKD and PKD/IC in patients with a PRRT2 sequence variant. This has important implications for counseling if genome-wide sequencing shows such variants in patients not presenting the PRRT2-related phenotypes.
Introduction
PRRT2 (MIM 614386) has been identified as a causal gene for benign infantile epilepsy (BIE), paroxysmal kinesigenic dyskinesia (PKD), and paroxysmal kinesigenic dyskinesia with infantile convulsions (PKD/IC) (Chen et al., 2011; Heron et al., 2012; Lee et al., 2012) . These clinical entities reflect the core of the PRRT2-related phenotypic spectrum (Ebrahimi-Fakhari et al., 2015) . Other epilepsies, movement disorders and (hemiplegic) migraine have been reported to be possibly related to PRRT2 sequence variants (Ebrahimi-Fakhari et al., 2015) .
PRRT2 encodes for proline-rich transmembrane protein 2 that interacts with SNAP25 in glutamatergic synapses in the brain to modulate glutamate release (Chen et al., 2011; Heron et al., 2012; Lee et al., 2012; Li et al., 2015) . PRRT2 sequence variants have been shown to result in a loss-of-function of PRRT2, impaired SNAP25 interaction, raised intracellular glutamate levels and increased neuronal hyperexcitability (Lee et al., 2012; Li et al., 2015) .
Chromosome 16p11.2 deletions including PRRT2 are associated with the 16p11.2 microdeletion syndrome (MIM 611913). We expected that 16p11.2 deletions are also associated with PRRT2-related phenotypes, because deletions and sequence variants of PRRT2 share an underlying loss-of-function disease mechanism. So far, only six cases with a 16p11.2 deletion and PKD (n = 4) or PKD/IC (n = 2) have been reported (Lipton and Rivkin, 2009; Dale et al., 2011 Dale et al., , 2012 Silveirahttps://doi.org/10.1016 /j.ejmg.2018 .08.002 Received 17 April 2018  Received in revised form 28 July 2018; Accepted 9 August 2018 Moriyama et al., 2013; Weber et al., 2013; Termsarasab et al., 2014) . Previous large 16p11.2 deletion cohort studies reported seizures in 24-31% of patients, dystonia in 1% and paroxysmal dyskinesia in 5% without classifying these phenotypes as BIE, PKD or PKD/IC (Shinawi et al., 2010; Steinman et al., 2016; Zufferey et al., 2012) .
We systematically evaluated the presence of the PRRT2-related phenotypes BIE, PKD, and PKD/IC in patients with a 16p11.2 deletion including PRRT2, and compared these frequencies with those seen in patients with a PRRT2 sequence variant.
Methods
We identified 129 Dutch-speaking patients with a 16p11.2 deletion including PRRT2 in seven Dutch university medical centers (UMCs). Five patients were not approached for participation (two were deceased, two had an additional disease-associated 22q11.2 deletion, and one was lost to follow-up before this study). Forty of 124 (32%) patients agreed to participate, including 33/40 (83%) index patients from 33 families.
Following the same strategy, we identified 43 patients with a PRRT2 sequence variant in three UMCs. One patient was involved in another study and not contacted. Fifteen (36%) patients agreed to participate, including 12/15 (80%) index patients from 12 families.
All patients or their parents/caregivers gave written consent for participation and completed a questionnaire containing (1) a PKD Screening questionnaire, (2) a Headache-Attributed Restriction, Disability, Social Handicap and Impaired Participation questionnaire and (3) questions on epilepsy (seizure onset, remission, frequency and semiology), school performance and development, height, weight and family history (Steiner et al., 2014; Tan et al., 2014) . An English version of the questionnaire is available on request.
Phenotypes were compared between index patients with a 16p11.2 deletion (n = 33) and those with a PRRT2 sequence variant (n = 12). To increase the validity of any observed differences, we compared the phenotypes of patients with a 16p11.2 deletion in our cohort (n = 33) with those of patients with a heterozygous PRRT2 sequence variant reported in the large review cohort of Ebrahimi-Fakhari (n = 1423, excluding patients with bi-allelic PRRT2 sequence variants (n = 15) or a 16p11.2 deletion (n = 6)) (Ebrahimi-Fakhari et al., 2015) .
Additional information on methods is given in the Supplementary Methods.
Results
We included 33 index patients with the recurrent ∼600 kb BP4-BP5 16p11.2 deletion (Supplementary Figure 1) and 12 index patients with a disease-associated PRRT2 sequence variant: c.649dupC; p.(Arg217-Profs*8) (n = 10), c.629dupC; p.(Ala211Serfs*14) (n = 1), or c.824C > T; p.(Ser275*) (n = 1) (NM_145239.2, Supplementary  Table 1 ). All variants were added to public databases (see Supplementary methods for more information). Patients with a 16p11.2 deletion most often underwent genetic testing because of developmental delay (87%), while those with a PRRT2 sequence variant were tested because of a movement disorder (55%) or epilepsy (45%) ( Table 1) .
Patients with a 16p11.2 deletion less often had a PRRT2-related phenotype than those with a PRRT2 sequence variant (9% vs. 100%, p < 0.001) (Table 1) . These phenotypes concerned BIE (9% vs. 33%, p = 0.069), PKD (0% vs. 50%, p < 0.001) and PKD/IC (0% vs. 17%, p = 0.067) (See Tables 2 and 3 for epilepsy and movement disorder phenotypes, respectively). Comparisons between patients with a 16p11.2 deletion in our cohort and those with a PRRT2 sequence variant from the review cohort showed significant differences for all PRRT2-related phenotypes ( Table 1) . The presence of other epilepsies, movement disorders, hemiplegic migraine and migraine as possible PRRT2-related phenotypes did not significantly differ between the three groups (Tables 1-3, see Supplementary Table 2 for migraine phenotypes).
Discussion
We found that only a minority of patients with a 16p11.2 deletion in our cohort suffered from BIE (9%) while none had PKD or PKD/IC. In comparison, patients with a PRRT2 sequence variant in our cohort (100%) and a review cohort (95%) had these PRRT2-related phenotypes significantly more often (Ebrahimi-Fakhari et al., 2015) .
It is unlikely that phenotypic differences between the two different genotype cohorts are due to differences in the underlying PRRT2 disease mechanism. First, PRRT2-related phenotypes occurred in both genotype groups in our study and other studies (Lipton and Rivkin, 2009; Dale et al., 2011 Dale et al., , 2012 Silveira-Moriyama et al., 2013; Weber et al., 2013; Termsarasab et al., 2014) . Second, both genotypes cause a loss-of-function of PRRT2. The p.(Arg217Profs*8) variant, found in most patients of our (83%) and the review (79%) cohort, results in a PRRT2 loss-of-function without a dominant-negative effect (Ebrahimi-Fakhari et al., 2015; Lee et al., 2012; Li et al., 2015) . Patients with 16p11.2 deletions have a 50% reduced expression of PRRT2 and other genes within the deletion region that probably explains their additional problems (Blumenthal et al., 2014) . In theory, the deletion of these other genes might have had a protective effect on the patients' phenotypes, but no clear evidence for this hypothesis exists so far.
It seems most likely that differences in ascertaining patients underlie the differences in PRRT2-related phenotypes observed in patients with a 16p11.2 deletion versus a PRRT2 sequence variant. The frequency of phenotypes has probably been overestimated in patients with a PRRT2 variant, who most often underwent genetic testing because of a movement disorder or epilepsy. The high frequency of the recurrent c.649dupC; p.(Arg217fs) PRRT2 variant in individuals included in the ExAC Database (1.3%, n = 401/32,017; Exac version 0.3.1) seems to support this hypothesis although the frequency in the gnomAD Database is substantially lower (0.05%, n = 8/14,859; gnomAD version r2.0.2) (Lek et al., 2016) . This difference might be related to the used data (whole exome versus whole genome data) or whether DNA amplification was performed, as previously suggested by the relatively high frequency of this variant in the Exome Variant Server database that uses amplification (Huguet et al., 2014) . A compatible influence of ascertainment might be present in the published review cohort. The inclusion of index cases in calculating penetrance of PRRT2 in other studies has probably resulted in an overestimated disease penetrance for PKD (60%) and BIE (60-90%) (Callenbach et al., 2005; Van Vliet et al., 2012) . A lower penetrance (48%) has been found in a single family with 23 relatives with PRRT2 sequence variants (Family 1, excluding the index patient) (Callenbach et al., 2005; De Vries et al., 2012) . Reduced penetrance is also known for other clinical features associated with the 16p11.2 BP4-BP5 deletion (Shinawi et al., 2010; Steinman et al., 2016; Zufferey et al., 2012) .
The low frequency of PRRT2-related phenotypes in our patients with 16p11.2 deletions is in line with two large previous studies showing the presence of any seizures in 24% (n = 49/195) and 27% (n = 22/83), paroxysmal dyskinesia in 5% (n = 12/233) and dystonia in 1% (n = 1/83), emphasizing the incomplete penetrance of BIE and PKD (Shinawi et al., 2010; Steinman et al., 2016; Zufferey et al., 2012) . However, in our small cohort, we might have underestimated the presence of PRRT2-related phenotypes. First, BIE occurred long time ago in some patients, leading to recall bias, and may have a low seizure-frequency, leading to missed diagnoses. Second, three patients had unwitnessed incidents, but these occurred too late for a diagnosis of BIE. Last, some patients were too young to fully exclude PKD. It is thus possible that the differences in frequencies between the two patient groups might be partly explained by under-recognition of PRRT2-related phenotypes in the 16p11.2 microdeletion patients.
The observation that the frequency of PRRT2-related phenotypes has thus far been overestimated in patients with a PRRT2 loss-offunction variant is important for counseling, because increasingly used whole exome sequencing (WES) may detect these variants as secondary findings. Doctors are tempted to use large cohort studies to counsel patients with such unexpected findings, but should realize that ascertainment bias is always present in these studies.
Conclusion
We conclude that 16p11.2 deletions including PRRT2 and PRRT2 sequence variants both lead to the PRRT2-associated phenotypes BIE, PKD or PKD/IC, but with incomplete penetrance. PRRT2-related phenotypes were more commonly found in patients with PRRT2 sequence variants, despite the shared underlying PRRT2 loss-of-function disease mechanism. Ascertainment bias has led to an overestimation of the penetrance of BIE, PKD and PKD/IC in patients with a PRRT2 sequence variant. This study is important for the clinical interpretation of PRRT2 sequence variants found by WES in patients without these specific phenotypes.
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